PASSAGE BIO, INC. Stock-Based Compensation
PASSAGE BIO, INC. (PASG) reported Stock-Based Compensation of $1.08 million for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-09-03
- PASSAGE BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $525.00K, a 43.12% decline year-over-year.
- PASSAGE BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $556.00K, a 35.20% decline year-over-year.
- PASSAGE BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $609.00K, a 51.16% decline year-over-year.
- PASSAGE BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $611.00K, a 56.36% decline year-over-year.
- PASSAGE BIO, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $10.92M, a 42.38% decline from fiscal 2022.
- PASSAGE BIO, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $18.95M, a 42.02% decline from fiscal 2021.
- PASSAGE BIO, INC. share-based payment arrangement, noncash expense for fiscal 2021 was $32.69M, a 124.22% increase from fiscal 2020.
- PASSAGE BIO, INC. share-based payment arrangement, noncash expense for fiscal 2020 was $14.58M, a 902.75% increase from fiscal 2019.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $525.00K derived: S-4/A 6 month − S-4 3 month · filed 2026-09-03 | $1.08M S-4/A · filed 2026-09-03 | $1.69M derived: sum of 3 quarters · filed 2026-09-03 | $2.30M derived: sum of 4 quarters · filed 2026-09-03 |
| 2026-03-31 | $556.00K S-4 · filed 2026-07-21 | $1.17M derived: sum of 2 quarters · filed 2026-09-03 | $1.78M derived: sum of 3 quarters · filed 2026-09-03 | $2.70M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-12-31 | $609.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $1.22M derived: sum of 2 quarters · filed 2026-09-03 | $2.14M derived: sum of 3 quarters · filed 2026-09-03 | $3.00M S-4/A · filed 2026-09-03 |
| 2025-09-30 | $611.00K derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-10 | $1.53M derived: sum of 2 quarters · filed 2026-09-03 | $2.39M 10-Q · filed 2025-11-10 | $3.64M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-06-30 | $923.00K derived: S-4/A 6 month − S-4 3 month · filed 2026-09-03 | $1.78M S-4/A · filed 2026-09-03 | $3.03M derived: sum of 3 quarters · filed 2026-09-03 | $4.43M derived: sum of 4 quarters · filed 2026-09-03 |
| 2025-03-31 | $858.00K S-4 · filed 2026-07-21 | $2.10M derived: sum of 2 quarters · filed 2026-09-03 | $3.50M derived: sum of 3 quarters · filed 2026-09-03 | $5.08M derived: sum of 4 quarters · filed 2026-09-03 |
| 2024-12-31 | $1.25M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-03 | $2.65M derived: sum of 2 quarters · filed 2026-09-03 | $4.22M derived: sum of 3 quarters · filed 2026-09-03 | $5.82M S-4/A · filed 2026-09-03 |
| 2024-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.98M derived: sum of 2 quarters · filed 2025-11-10 | $4.57M 10-Q · filed 2025-11-10 | $6.14M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $3.17M 10-Q · filed 2025-08-12 | $4.74M derived: sum of 3 quarters · filed 2025-08-12 | $7.57M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.59M 10-Q · filed 2025-05-13 | $3.17M derived: sum of 2 quarters · filed 2025-05-13 | $5.99M derived: sum of 3 quarters · filed 2025-05-13 | $9.73M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $4.39M derived: sum of 2 quarters · filed 2025-03-04 | $8.14M derived: sum of 3 quarters · filed 2025-03-04 | $10.92M 10-K · filed 2025-03-04 |
| 2023-09-30 | $2.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $6.57M derived: sum of 2 quarters · filed 2024-11-13 | $9.35M 10-Q · filed 2024-11-13 | $12.83M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $3.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $6.53M 10-Q · filed 2024-08-08 | $10.00M derived: sum of 3 quarters · filed 2024-08-08 | $12.87M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.78M 10-Q · filed 2024-05-14 | $6.26M derived: sum of 2 quarters · filed 2024-05-14 | $9.12M derived: sum of 3 quarters · filed 2024-05-14 | $15.40M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-04 | $6.34M derived: sum of 2 quarters · filed 2024-03-04 | $12.62M derived: sum of 3 quarters · filed 2024-03-04 | $18.95M 10-K · filed 2024-03-04 |
| 2022-09-30 | $2.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $9.14M derived: sum of 2 quarters · filed 2023-11-13 | $15.48M 10-Q · filed 2023-11-13 | $23.05M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $6.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $12.62M 10-Q · filed 2023-08-07 | $20.19M derived: sum of 3 quarters · filed 2023-08-07 | $27.00M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $6.34M 10-Q · filed 2023-05-11 | $13.91M derived: sum of 2 quarters · filed 2023-05-11 | $20.73M derived: sum of 3 quarters · filed 2023-05-11 | $29.29M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $14.39M derived: sum of 2 quarters · filed 2023-03-06 | $22.95M derived: sum of 3 quarters · filed 2023-03-06 | $32.69M 10-K · filed 2023-03-06 |
| 2021-09-30 | $6.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $15.38M derived: sum of 2 quarters · filed 2022-11-10 | $25.12M 10-Q · filed 2022-11-10 | $29.44M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $8.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $18.30M 10-Q · filed 2022-08-04 | $22.63M derived: sum of 3 quarters · filed 2022-08-04 | $26.66M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $9.74M 10-Q · filed 2022-05-16 | $14.06M derived: sum of 2 quarters · filed 2022-05-16 | $18.10M derived: sum of 3 quarters · filed 2022-05-16 | $21.95M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $8.36M derived: sum of 2 quarters · filed 2022-03-03 | $12.21M derived: sum of 3 quarters · filed 2022-03-03 | $14.58M 10-K · filed 2022-03-03 |
| 2020-09-30 | $4.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $7.89M derived: sum of 2 quarters · filed 2021-11-04 | $10.26M 10-Q · filed 2021-11-04 | $11.29M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $3.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $6.22M 10-Q · filed 2021-08-05 | $7.26M derived: sum of 3 quarters · filed 2021-08-05 | $7.35M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $2.37M 10-Q · filed 2021-05-05 | $3.40M derived: sum of 2 quarters · filed 2021-05-05 | $3.50M derived: sum of 3 quarters · filed 2021-05-05 | $3.59M derived: sum of 4 quarters · filed 2021-05-05 |
| 2019-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | $1.13M derived: sum of 2 quarters · filed 2021-03-03 | $1.22M derived: sum of 3 quarters · filed 2021-03-03 | $1.45M 10-K · filed 2021-03-03 |
| 2019-09-30 | $95.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $187.00K derived: sum of 2 quarters · filed 2020-11-10 | $418.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $92.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $323.00K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $231.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |